Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus.
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
An outbreak of paralytic poliomyelitis occurred in the Dominican Republic (13 confirmed cases) and Haiti (8 confirmed cases, including 2 fatal cases) during 2000-2001. All but one of the patients were either unvaccinated or incompletely vaccinated children, and cases occurred in communities with very low (7 to 40%) rates of coverage with oral poliovirus vaccine (OPV). The outbreak was associated with the circulation of a derivative of the type 1 OPV strain, probably originating from a single OPV dose given in 1998-1999. The vaccine-derived poliovirus associated with the outbreak had biological properties indistinguishable from those of wild poliovirus.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The first outbreak of cVDPV was identified in the Dominican Republic and Haiti between 2000 and 2001.”
From The Fight against Poliovirus Is Not Over (2023) · cites this paper as [91]
In the citing paper
“In general, the VP1 sequences examined from cVDPV isolates differed from parental OPV strains by only 1–3.5%, suggesting that reversion to the attenuated phenotype of Sabin strains occurs with circulation times of 1–4 years [91,92,93,95,100].”
From The Fight against Poliovirus Is Not Over (2023) · cites this paper as [91]
In the citing paper
“As with the other epidemics in Egypt and Hispaniola, VDPV circulated in a province of Madagascar with low OPV coverage (6,7).”
From Recombinant Vaccine–Derived Poliovirus in Madagascar (2003) · cites this paper as [7]
In the citing paper
“Most VDPV strains described as OPV/HEV-C recombinants were isolated in countries in which wild PVs have been eradicated”
From Co-Circulation and Evolution of Polioviruses and Species C Enteroviruses in a District of Madagascar (2007) · cites this paper as [12]
In the citing paper
“The cVDPV had recovered two of the most important biological properties of wild PV: the capacity to cause severe paralytic disease in humans and the capacity for extensive human-to-human transmission.”
From Recombination between Poliovirus and Coxsackie A Viruses of Species C: A Model of Viral Genetic Plasticity and Emergence (2011) · cites this paper as [83]
31 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Oberste, M. S., Maher, K., Kilpatrick, D. R., & Pallansch, M. A. (1999) · Journal of Virology · doi:10.1128/jvi.73.3.1941-1948.1999 · Cited by 866
Self-citationStrebel, P. M., Sutter, R. W., Cochi, S. L., Biellik, R. J., Brink, E. W., Kew, O. M., Pallansch, M. A., Orenstein, W. A., & Hinman, A. R. (1992) · Clinical Infectious Diseases · doi:10.1093/clinids/14.2.568 · Cited by 337
Self-citationKawamura, N., Kohara, M., Abe, S., Komatsu, T., Tago, K., Arita, M., & Nomoto, A. (1989) · Journal of Virology · doi:10.1128/jvi.63.3.1302-1309.1989 · Cited by 232
NATHANSON, N., & MARTIN, J. R. (1979) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a112848 · Cited by 214
Antigenic Structure of Picornaviruses
Minor, P. D. (1990) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-75602-3_5 · Cited by 187
Dual Stem Loops within the Poliovirus Internal Ribosomal Entry Site Control Neurovirulence
Gromeier, M., Bossert, B., Arita, M., Nomoto, A., & Wimmer, E. (1999) · Journal of Virology · doi:10.1128/jvi.73.2.958-964.1999 · Cited by 160
Molecular epidemiology of polioviruses
Kew, O. M., Mulders, M. N., Lipskaya, G. Y., da Silva, E. E., & Patlansch, M. A. (1995) · Seminars in Virology · doi:10.1016/s1044-5773(05)80017-4 · Cited by 157
Self-citationDeterminants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin vaccine
Bouchard, M. J., Lam, D. H., & Racaniello, V. R. (1995) · Journal of Virology · doi:10.1128/jvi.69.8.4972-4978.1995 · Cited by 140
Comparative study of five methods for intratypic differentiation of polioviruses
van der Avoort, H. G., Hull, B. P., Hovi, T., Pallansch, M. A., Kew, O. M., Crainic, R., Wood, D. J., Mulders, M. N., & van Loon, A. M. (1995) · Journal of Clinical Microbiology · doi:10.1128/jcm.33.10.2562-2566.1995 · Cited by 122
Self-citationMinor, P. D., & Dunn, G. (1988) · Journal of General Virology · doi:10.1099/0022-1317-69-5-1091 · Cited by 120
Research works printed but not linked: 5
- Andrus J. K., Strebel P. M., de Quadros C. A., Olive J. M., Bull. WHO 73, 33 (1995).
- Supplementary figures and details of experimental procedures are available on Science Online at www.sciencemag.org/cgi/content/full/1068284/DC1.
- Minor P. D., Curr. Top. Microbiol. Immunol. 161, 121 (1990).
- ___, Morb. Mortal. Wkly. Rep. 50, 41 (2001).
- Wood D. J., Sutter R. W., Dowdle W. R., Bull. WHO 78, 347 (2000).
Cited by
Items 201–300 of 594
Genus-Specific Substitution Rate Variability among Picornaviruses
Hicks, A. L., & Duffy, S. (2011) · Journal of Virology · doi:10.1128/jvi.02535-10 · Cited by 41
“Human picornaviruses produce symptoms ranging from mild respiratory illness to hemorrhagic conjunctivitis, myocarditis, acute flaccid paralysis, and neonatal organ failure (19, 27, 28, 33, 40, 41).”
BackgroundPoliovirus vaccination during the endgame: insights from integrated modeling
Tebbens, R. J. D., & Thompson, K. M. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1322514 · Cited by 36
“In addition, in populations with low immunity, OPV can continue to infect individuals and over time lose its attenuating mutations and evolve toward cVDPVs that behave like WPVs and can cause outbreaks [4,5,17].”
BackgroundKalkowska, D. A., Pallansch, M. A., Cochi, S. L., Kovacs, S., Wassilak, S. G. F., & Thompson, K. M. (2020) · Risk Analysis · doi:10.1111/risa.13555 · Cited by 37
Self-citationReflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame
Thompson, K. M., & Kalkowska, D. A. (2020) · Risk Analysis · doi:10.1111/risa.13484 · Cited by 37
“When OPV-using countries do not achieve and maintain high coverage, the transmission of OPV-related viruses can lead to cVDPV outbreaks (Kew et al., 2002).”
BackgroundIcenogle, J. P., Frey, T. K., Abernathy, E. S., Reef, S. E., Schnurr, D. P., & Stewart, J. A. (2006) · Clinical Infectious Diseases · doi:10.1086/505945 · Cited by 35
Cheng, Z., Yang, J., Xia, H., Qiu, Y., Wang, Z., Han, Y., Xia, X., Qin, C., Hu, Y., & Zhou, X. (2013) · Journal of Virology · doi:10.1128/jvi.00245-13 · Cited by 37
“Picorna-like viruses in the Picornavirales order include numerous important pathogens that are responsible for diseases in humans, such as poliomyelitis (2), hand-foot-andmouth disease (3), hepatitis A (4), upper respiratory illness (5), myocarditis (6), diseases in insects, such as sacbrood (7), and diseases in plant…”
BackgroundZhang, Y., Yan, D., Zhu, S., Wen, N., Li, L., Wang, H., Liu, J., Ye, X., Ding, Z., Wang, D., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/657410 · Cited by 35
Self-citationOtten, M. W., Okwo‐Bele, J., Kezaala, R., Biellik, R., Eggers, R., & Nshimirimana, D. (2003) · The Journal of Infectious Diseases · doi:10.1086/368272 · Cited by 33
“Fortunately, momentum is building from three directions to increase routine coverage to 80% in most African countries by 2005—the polio eradication initiative (to prevent circulating vaccine-derived poliovirus from emerging [19]), the measles initiative (to maintain measles deaths near zero), and GAVI (increased routi…”
BackgroundEmergence of Vaccine-derived Polioviruses, Democratic Republic of Congo, 2004–2011
Gumede, N., Lentsoane, O., Burns, C. C., Pallansch, M. A., de Gourville, E. M., Riziki, Y., Muyembe-Tamfum, J. J., Puren, A. J., Schoub, B. D., & Venter, M. (2013) · Emerging infectious diseases · doi:10.3201/eid1910.130028 · Cited by 35
“Discontinuation of the type 2 component of OPV is being considered as a strategy for reducing the frequency of circulating VDPV2 emergence (12).”
BackgroundSelf-citationPolicy decision options during the first 5 years following certification of polio eradication.
Sangrujee, N., Tebbens, R. J. D., Cáceres, V. M., & Thompson, K. M. (2003) · PubMed · Cited by 33
Karakasiliοtis, I., Markoulatos, P., & Katsorchis, T. (2003) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2003.09.009 · Cited by 46
Tsugawa, T., Numata‐Kinoshita, K., Honma, S., Nakata, S., Tatsumi, M., Sakai, Y., Natori, K., Takeda, N., Kobayashi, S., & Tsutsumi, H. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.1.177-182.2006 · Cited by 36
“Similar recombination cases for other single-stranded RNA viruses, such as astrovirus (4), poliovirus (22), echovirus (32), and enteroviruses (37), have been reported.”
BackgroundCan We Capitalize on the Virtues of Vaccines? Insights from the Polio Eradication Initiative
Aylward, R. B., & Heymann, D. L. (2005) · American Journal of Public Health · doi:10.2105/ajph.2004.055897 · Cited by 37
Surveillance of acute flaccid paralysis in the Marches region (Italy): 1997–2007
the AFP Study Group, D’Errico, M. M., Barbadoro, P., Bacelli, S., Esposto, E., Moroni, V., Scaccia, F., Tantucci, L., & Prospero, E. (2008) · BMC Infectious Diseases · doi:10.1186/1471-2334-8-135 · Cited by 33
“Polio outbreak can be caused by circulating vaccine derived poliovirus, as those reported in Egypt [15], Hispaniola [16] and Philippines [17] so, also if the OPV has been discontinued in Italy, people from foreign countries might contribute to the spread of these viruses, in these cases environmental surveillance of p…”
The Challenge of Global Poliomyelitis Eradication
Garon, J. R., Cochi, S. L., & Orenstein, W. A. (2015) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.07.003 · Cited by 33
“The largest risk factor for generation of cVDPVs is low overall population immunity allowing vaccine viruses to mutate and spread within a susceptible population.(16,17) cVDPV outbreaks have occurred in areas with complex challenges, such as those”
Self-citationSurveillance of acute flaccid paralysis in Akwa Ibom State, Nigeria 2004-2009
Bassey, B., Gasasira, A. N., Mitula, P., Frankson, U., & Adeniji, J. A. (2011) · Pan African Medical Journal · doi:10.4314/pamj.v9i1.71208 · Cited by 32
“It is important to note that lowered immunization coverage may also have serious consequences in countries that use OPV, as was recently demonstrated by outbreaks of poliomyelitis due to circulating vaccine derived polioviruses (cVDPV) in Nigeria [17], Hispaniola, (Dominican Republic and Haiti) [18], the Philippines […”
BackgroundComplete genomic characterization of an intertypic Sabin 3/Sabin 2 capsid recombinant
Dedepsidis, E., Pliaka, V., Kyriakopoulou, Z., Brakoulias, C., Levidiotou-Stefanou, S., Pratti, A., Mamuris, Z., & Markoulatos, P. (2008) · FEMS Immunology & Medical Microbiology · doi:10.1111/j.1574-695x.2008.00381.x · Cited by 45
“However, this advantage has proved to be a drawback, as it was the underlying cause of recent cVDPV outbreaks in regions with gaps in OPV coverage (Kew et al., 2002; Rousset et al., 2003; Shimizu et al., 2004).”
BackgroundBuisman, A., Abbink, F., Schepp, R. M., Sonsma, J. A. J., Herremans, T., & Kimman, T. G. (2008) · The Journal of Infectious Diseases · doi:10.1086/527487 · Cited by 33
“This is a problem for poliovirus eradication, because OPV can evolve into circulating vaccine-derived polioviruses, which have recently caused outbreaks in Hispaniola and Egypt [7, 8].”
BackgroundEnteroviruses and Parechoviruses
Dunn, J. J. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.dmih2-0006-2015 · Cited by 37
Tebbens, R. J. D., Hampton, L. M., Wassilak, S. G. F., Pallansch, M. A., Cochi, S. L., & Thompson, K. M. (2016) · Journal of Vaccines & Vaccination · doi:10.4172/2157-7560.1000340 · Cited by 32
“defined as the occurrence of prevalence of virus in the last reversion stage above the transmission threshold) only when OPV-related viruses circulate in a population with low enough population immunity to sustain transmission [15,16,20], consistent with the evidence from cVDPV outbreaks [31-33].”
ResultSelf-citationKimman, T. G., & Boot, H. J. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70603-x · Cited by 36
Rezapkin, G. V., Martín, J. E.-S., & Chumakov, K. (2005) · Biologicals · doi:10.1016/j.biologicals.2004.11.001 · Cited by 35
Poliovirus, Pathogenesis of Poliomyelitis, and Apoptosis
Blondel, B., Colbère-Garapin, F., Couderc, T., Wirotius, A., & Guivel‐Benhassine, F. (2005) · Springer eBooks · doi:10.1007/3-540-27320-4_2 · Cited by 46
The Fight against Poliovirus Is Not Over
Mbani, C. J., Nekoua, M. P., Moukassa, D., & Hober, D. (2023) · Microorganisms · doi:10.3390/microorganisms11051323 · Cited by 34
“Affected patients were either partially vaccinated or unvaccinated [91].”
BackgroundPotential Future Use, Costs, and Value of Poliovirus Vaccines
Thompson, K. M., & Kalkowska, D. A. (2020) · Risk Analysis · doi:10.1111/risa.13557 · Cited by 32
Formulation technologies for oral vaccines
New, R. R. C. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13352 · Cited by 34
Immune surveillance for vaccine-preventable diseases
den Hartog, G., van Binnendijk, R. S., Buisman, A., Berbers, G. A. M., & van der Klis, F. R. M. (2020) · Expert Review of Vaccines · doi:10.1080/14760584.2020.1745071 · Cited by 33
“possibility of reverting to infectious virus [80,82].”
Valesano, A. L., Taniuchi, M., Fitzsimmons, W. J., Islam, M. O., Ahmed, T., Zaman, K., Haque, R., Wong, W., Famulare, M., & Lauring, A. S. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.10.011 · Cited by 31
Khetsuriani, N., Helfand, R. F., Pallansch, M. A., Kew, O. M., Fowlkes, A., Oberste, M. S., Tukei, P. M., Muli, J., Makokha, E. P., & Gary, H. E. (2009) · BMC Infectious Diseases · doi:10.1186/1471-2334-9-136 · Cited by 30
“To fully characterize the patterns of VDPV excretion among HIV-infected persons and to quantify the risk of long-term VDPV replication in this group, larger studies that cover the full range of HIV disease are needed.”
BackgroundInfluentialSelf-citationEradicating polio: today's challenges and tomorrow's legacy
Aylward, R. B. (2006) · Annals of Tropical Medicine and Parasitology · doi:10.1179/136485906x97354 · Cited by 30
Breman, J. G., de Quadrós, C. A., Dowdle, W. R., Foege, W. H., Henderson, D. A., John, T. J., & Levine, M. M. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000405 · Cited by 35
“Recognition that vaccine-derived poliovirus could cause epidemics of AFP reinforced the need for flexible research efforts to respond expeditiously to emerging needs [19,20].”
BackgroundXiao, Y., & Daniell, H. (2017) · Vaccine · doi:10.1016/j.vaccine.2016.12.061 · Cited by 32
“Vaccine associated paralytic poliomyelitis among recipients of OPV was observed in several outbreak areas in the USA [6,7], Haiti [8], Dominican Republic [8], India [9], Phillipines [10], African continent [11,12] and many other global regions.”
BackgroundSamoilovich, E., Roivainen, M., Titov, L. P., & Hovi, T. (2003) · Journal of Medical Virology · doi:10.1002/jmv.10480 · Cited by 30
Generation and analysis of an RNA vaccine that protects against coxsackievirus B3 challenge
Hunziker, I. P., Harkins, S., Feuer, R., Cornell, C. T., & Whitton, J. L. (2004) · Virology · doi:10.1016/j.virol.2004.09.035 · Cited by 34
Envelope Exchange for the Generation of Live-Attenuated Arenavirus Vaccines
Bergthaler, A., Gerber, N. U., Merkler, D., Horváth, E. J., de la Torre, J. C., & Pinschewer, D. D. (2006) · PLoS Pathogens · doi:10.1371/journal.ppat.0020051 · Cited by 30
“Conversely, even RNA viruses carrying multiple attenuating point mutations are prone to reversion [44].”
BackgroundUnjust embargo of aid for Haiti
Farmer, P. E., Fawzi, M. C. S., & Nevil, P. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12380-x · Cited by 30
Riquet, F. B., Blanchard, C., Jegouic, S., Balanant, J., Guillot, S., Vibet, M.-A., Rakoto-Andrianarivelo, M., & Delpeyroux, F. (2008) · Journal of Virology · doi:10.1128/jvi.00239-08 · Cited by 29
Current Progress in the Development of mRNA Vaccines Against Bacterial Infections
Khlebnikova, A., Kirshina, A., Zakharova, N. A., Ivanov, R. A., & Reshetnikov, V. V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313139 · Cited by 37
“On the other hand, attenuated vaccines show genetic instability during long periods of time, thereby posing the risk that the attenuated strain will revert to virulent status [185,186].”
A vision of a world without polio: The OPV cessation strategy
Heymann, D. L., Sutter, R. W., & Aylward, R. B. (2006) · Biologicals · doi:10.1016/j.biologicals.2006.03.005 · Cited by 30
Self-citationKalkowska, D. A., Tebbens, R. J. D., & Thompson, K. M. (2012) · American Journal of Epidemiology · doi:10.1093/aje/kwr399 · Cited by 29
Search for poliovirus long-term excretors among patients affected by agammaglobulinemia
Fiore, L., Plebani, A., Buttinelli, G., Fiore, S., Donati, V., Marturano, J., Soresina, A., Martire, B., Azzari, C., Nigro, G., et al. (2004) · Clinical Immunology · doi:10.1016/j.clim.2003.11.011 · Cited by 30
Zhang, Y., Zhu, S., Yan, D., Liu, G., Bai, R., Wang, D., Chen, L., Zhu, H., An, H., Kew, O. M., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015300 · Cited by 35
“Two genetic characteristics, nucleotide mutations at key neurovirulence determination sites and genetic rearrangements with human enterovirus C species, seem to underlie the occurrence of poliomyelitis outbreaks associated with cVDPVs [7,12,13].”
BackgroundSelf-citationLaassri, M., Lottenbach, K. R., Belshe, R. B., Rennels, M. B., Plotkin, S. A., & Chumakov, K. (2006) · The Journal of Infectious Diseases · doi:10.1086/503366 · Cited by 29
Minor, P. D., Dunn, G., Ramsay, M. E., & Brown, D. (2005) · Journal of Medical Virology · doi:10.1002/jmv.20250 · Cited by 28
“recombined with another unknown virus [Kew et al., 2002], and hypogammaglobulinaemic patients can occasionally become long term excretors of poliovirus”
BackgroundYan, D., Li, L., Zhu, S., Zhang, Y., An, J., Wang, D., Wen, N., Jorba, J. C., Liu, W. Y., Zhong, G., et al. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.00712-10 · Cited by 28
“This is in distinct contrast to the serial recombination with HEVs-C that is typically found during circulation of most cVDPVs (18, 19, 32, 34, 46) and WPVs (24).”
BackgroundResultInfluentialSelf-citationPolio eradication: finishing the job and protecting the investment.
Heymann, D. L. (2004) · Europe PMC (PubMed Central) · doi:10.1590/s0042-96862004000100002 · Cited by 28
“16–23, (1, 2)) The operational challenge during this period will be to maintain high levels of polio immunization within routine immunization programmes and to keep polio surveillance systems in place.”
BackgroundEvolution of a rare vaccine-derived multirecombinant poliovirus
Karakasiliοtis, I., Paximadi, E., & Markoulatos, P. (2005) · Journal of General Virology · doi:10.1099/vir.0.80823-0 · Cited by 33
“…have been identified in one isolate, reflecting the occurrence of multiple recombination events (Georgescu et al., 1994, 1995; Guillot et al., 2000; Cuervo et al., 2001; Georgopoulou & Markoulatos, 2001; Kew et al., 2002; Blomqvist et al., 2003; Liu et al., 2003; Karakasiliotis et al., 2004).”
BackgroundInfluentialCooper, L., Erbeto, T. B., Danzomo, A. A., Abdullahi, H., Boateng, K., Adamu, U. S., Shuaib, F. M. B., Ndoutabé, M., Gray, E. J., Bandyopadhyay, A. S., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00688-6 · Cited by 27
Arita, M., Kilpatrick, D. R., Nakamura, T., Burns, C. C., Bukbuk, D. N., Oderinde, B. S., Oberste, M. S., Kew, O. M., Pallansch, M. A., & Shimizu, H. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.02384-14 · Cited by 28
“Sequencing is essential for classifying PV isolates into vaccine strains, wild-type strains, and circulating vaccine-derived PV (VDPV) strains and for determining the necessity of additional vaccination plans by identifying virus reservoirs, along with molecular epidemiological methods (4).”
BackgroundSelf-citationRetrospective Characterization of a Vaccine-Derived Poliovirus Type 1 Isolate from Sewage in Greece
Dedepsidis, E., Kyriakopoulou, Z., Pliaka, V., Kottaridi, C., Bolanaki, E., Levidiotou-Stefanou, S., Komiotis, D., & Markoulatos, P. (2007) · Applied and Environmental Microbiology · doi:10.1128/aem.00535-07 · Cited by 30
Cassemiro, K. M. S. D. M., Burlandy, F. M., Barbosa, M. R. F., Chen, Q., Jorba, J. C., Hachich, E. M., Sato, M. I. Z., Burns, C. C., & da Silva, E. E. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152251 · Cited by 31
“As a consequence of the genetic instability of OPV strains, vaccine-derived polioviruses (VDPV) have emerged on occasion in immunodeficient patients or under conditions of low population immunity, low vaccine coverage, poor sanitation and tropical conditions [7–9].”
BackgroundSelf-citationHovi, T., Lindholm, N., Savolainen, C., Stenvik, M., & Burns, C. C. (2004) · Journal of General Virology · doi:10.1099/vir.0.19518-0 · Cited by 30
“In these calculations a constant rate of accumulation of synonymous substitutions (molecular clock) is assumed to exist, and for the gene of poliovirus VP1, rates of 1–2 % change year21 have been proposed (Kew et al., 1998, 2002; Gavrilin et al., 2000).”
BackgroundSelf-citationMangal, T. D., Aylward, R. B., & Grassly, N. C. (2013) · American Journal of Epidemiology · doi:10.1093/aje/kwt203 · Cited by 28
A Health Economic Analysis for Oral Poliovirus Vaccine to Prevent COVID‐19 in the United States
Thompson, K. M., Kalkowska, D. A., & Badizadegan, K. (2020) · Risk Analysis · doi:10.1111/risa.13614 · Cited by 27
Nagata, N., Iwasaki, T., Ami, Y., Sato, Y., Hatano, I., Harashima, A., Suzaki, Y., Yoshii, T., Hashikawa, T., Sata, T., et al. (2004) · Virology · doi:10.1016/j.virol.2003.12.008 · Cited by 27
Zhang, Y., Wang, H., Zhu, S., Li, Y., Li, S., Liu, Y., Liu, G., Nishimura, Y., Chen, L., Yan, D., et al. (2009) · Journal of General Virology · doi:10.1099/vir.0.014258-0 · Cited by 26
“Two genetic characteristics, nucleotide mutations and genetic rearrangements, seem to underlie the occurrence of poliomyelitis outbreaks associated with cVDPVs (Kew et al., 2002, 2004, 2005).”
BackgroundSelf-citationZhang, Y., Yan, D., Zhu, S., Nishimura, Y., Ye, X., Wang, D., Jorba, J. C., Zhu, H., An, H., Shimizu, H., et al. (2015) · Scientific Reports · doi:10.1038/srep17291 · Cited by 25
Self-citationA novel enterovirus species identified from severe diarrheal goats
Wang, M., He, J., Lu, H., Liu, Y., Deng, Y., Zhu, L., Guo, C., Tu, C., & Wang, X. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174600 · Cited by 25
Arita, M., Ling, H., Yan, D., Nishimura, Y., Yoshida, H., Wakita, T., & Shimizu, H. (2009) · BMC Infectious Diseases · doi:10.1186/1471-2334-9-208 · Cited by 26
Self-citationAylward, R. B., & Cochi, S. L. (2004) · Europe PMC (PubMed Central) · Cited by 25
Self-citationBurns, C. C., Kilpatrick, D. R., Iber, J. C., Chen, Q., & Kew, O. M. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3292-4_9 · Cited by 26
Self-citationMolecular basis of genetic variation of viruses
Domingo, E. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816331-3.00002-7 · Cited by 31
“Several recent poliomyelitis outbreaks have been associated with recombinants between oral poliovirus vaccine (OPV) viruses and other circulating enteroviruses (Gavrilin et al., 2000; Kew et al., 2002; Oberste et al., 2004; Muslin et al., 2015).”
Snider, C. J., Boualam, L., Tallis, G. F., Takashima, Y., Abeyasinghe, R. R., Lo, Y.-R. J., Grabovac, V., Avagyan, T., Aslam, S. K., Eltayeb, A. O., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.02.022 · Cited by 26
Tebbens, R. J. D., Pallansch, M. A., Wassilak, S. G. F., Cochi, S. L., & Thompson, K. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130123 · Cited by 25
Self-citationSeroprevalence of poliovirus antibodies amongst children in Zaria, Northern Nigeria
Giwa, F., Olayinka, A., & Ogunshola, F. T. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.09.023 · Cited by 26
“These findings are in line with recent studies suggesting that the key risk factor for cVDPV emergence and spread is low population immunity [22–24].”
Resultvan der Sanden, S., Pallansch, M. A., van de Kassteele, J., El-Sayed, N., Sutter, R. W., Koopmans, M., & van der Avoort, H. (2009) · Journal of Virology · doi:10.1128/jvi.02388-08 · Cited by 26
“In the present study, the mean overall VP1 synonymous- and nonsynonymous-mutation rates are severalfold higher than those reported previously from circulating viruses or those in immunodeficient patients (18, 25, 26, 28, 31, 42, 43).”
BackgroundSelf-citationGlobal Eradication of Poliovirus:History and Rationale
Dowdle, W. R., & Cochi, S. L. (2014) · Molecular Biology of Picornavirus · doi:10.1128/9781555817916.ch38 · Cited by 24
Self-citationGenomic Analysis of Recombinant Sabin Clinical Isolates
Paximadi, E., Karakasiliοtis, I., Mamuris, Z., Stathopoulos, C., Krikelis, V., & Markoulatos, P. (2006) · Virus Genes · doi:10.1007/s11262-005-6877-1 · Cited by 30
Korotkova, E., Laassri, M., Zagorodnyaya, T., Petrovskaya, S., Rodionova, E., Cherkasova, E., Gmyl, A., Ivanova, O., Eremeeva, T., Lipskaya, G., et al. (2017) · Viruses · doi:10.3390/v9110353 · Cited by 23
“Thus, for example, such recombinants of type 1, which triggered polio outbreaks in the Dominican Republic and Philippines in 2000–2001, demonstrated a replacement of a significant portion of their P2 region [25,26]; the genomes of type 2 recombinants involved in several outbreaks were deprived of their homotypic 3′-en…”
BackgroundThompson, K. M., & Tebbens, R. J. D. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-1113-7 · Cited by 25
“Multiple cVDPV outbreaks (defined as transmission that led to 1 or more cases of paralytic poliomyelitis) occurred to date [5–8], including re-established (cVDPV2) in Northern Nigeria since 2005 [9, 10].”
BackgroundZhang, Y., Sun, Q., Cui, H., Yan, D., Fan, Q., Song, Y., Zhu, S., Li, X., Huang, G., Ji, T., et al. (2016) · Scientific Reports · doi:10.1038/srep33595 · Cited by 24
Martinez, C. V., Old, M. O., Kwock, D., Khan, S. S., García, J. J., Chan, C. S., Webster, R. L., Halpern, M. S., & Maldonado, Y. (2004) · The Journal of Infectious Diseases · doi:10.1086/421703 · Cited by 23
Tang, J.-J., Yoshida, H., Ding, Z., Tao, Z., Zhang, J., Tian, B.-J., Zhao, Z., & Zhang, L. (2014) · Scientific Reports · doi:10.1038/srep06058 · Cited by 25
Sutter, R. W., Kew, O. M., Cochi, S. L., & Aylward, R. B. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35761-6.00048-1 · Cited by 33
Self-citationEnding Use of Oral Poliovirus Vaccine - A Difficult Move in the Polio Endgame
Pallansch, M. A. (2018) · New England Journal of Medicine · doi:10.1056/nejmp1808903 · Cited by 21
Self-citationThompson, K. M., & Badizadegan, K. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2361060 · Cited by 21
“Low RI coverage and reduction of the intensity of SIAs in Hispaniola led to the first reported out-break of a type 1 cVDPV (i.e. cVDPV1) in 2001, with type 1 polio cases associated with poliovirus transmission reported by PAHO [112].”
The Potential Benefits of a new Poliovirus Vaccine for Long-Term Poliovirus Risk Management
Tebbens, R. J. D., & Thompson, K. M. (2016) · Future Microbiology · doi:10.2217/fmb-2016-0126 · Cited by 22
Brouwer, L., van der Sanden, S. M. G., Calis, J. C. J., Bruning, A. H. L., Wang, S., Wildenbeest, J., Rebers, S. P. H., Phiri, K. S., Westerhuis, B. M., van Hensbroek, M. B., et al. (2018) · Archives of Virology · doi:10.1007/s00705-018-3878-7 · Cited by 21
Coria, L. M., Risso, G. S., Guaimas, F. F., Ferrero, M. C., Bruno, L. A., Pasquevich, K. A., & Cassataro, J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.11.025 · Cited by 21
Boot, H. J., Schepp, R. M., Nunen, F. J. H. B. V. A.-V., & Kimman, T. G. (2003) · Journal of Virological Methods · doi:10.1016/j.jviromet.2003.10.008 · Cited by 21
Human monoclonal antibodies that neutralize vaccine and wild-type poliovirus strains
Puligedda, R. D., Kouiavskaia, D. V., Adekar, S. P., Sharma, R., Kattala, C. D., Rezapkin, G. V., Bidzhieva, B., Dessain, S. K., & Chumakov, K. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.05.005 · Cited by 23
Comparison of poliovirus recombinants: accumulation of point mutations provides further advantages
Savolainen‐Kopra, C., Samoilovich, E., Kahelin, H., Hiekka, A., Hovi, T., & Roivainen, M. (2009) · Journal of General Virology · doi:10.1099/vir.0.010942-0 · Cited by 23
Current immunizations for travel
Kirkpatrick, B. D., & Alston, W. K. (2003) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200310000-00001 · Cited by 21
Oral poliovaccine: will it help eradicate polio or cause the next epidemic?
Shulman, L. M., Manor, Y., Sofer, D., Swartz, T. A., & Mendelson, E. (2006) · PubMed · Cited by 25
Microbiological Quality of Water
(2022) · Wiley eBooks · doi:10.1002/9781119820086.ch3 · Cited by 21
Yoshida, A., Okamura, S., Torii, S., Komatsu, S., Miyazato, P., Sasaki, H., Ueno, S., Suzuki, H., Kamitani, W., Ono, C., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105412 · Cited by 20
Adeniji, J. A., & Faleye, T. O. C. (2014) · Journal of Virological Methods · doi:10.1016/j.jviromet.2014.07.016 · Cited by 22
Caraballo, D. A., Lema, C. L., Novaro, L., Dohmen, F. G., Russo, S., Beltrán, F. J., Palacios, G. F., & Cisterna, D. M. (2021) · Viruses · doi:10.3390/v13122484 · Cited by 27
“An example of these unexpected results is the polio epidemics caused by the recombination of a vaccine strain with endogenous enteroviruses [75].”
BackgroundVirus-like particles in picornavirus vaccine development
Dong, H., Guo, H., & Sun, S. (2014) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-014-5639-1 · Cited by 20
Schein, C. H., Volk, D. E., Oezguen, N., & Paul, A. V. (2006) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.20891 · Cited by 21
Tebbens, R. J. D., & Thompson, K. M. (2017) · MDM Policy & Practice · doi:10.1177/2381468317697002 · Cited by 20
Generated Randomly and Selected Functionally? The Nature of Enterovirus Recombination
Alnaji, F. G., Bentley, K., Pearson, A., Woodman, A., Moore, J. D., Fox, H., Macadam, A. J., & Evans, D. J. (2022) · Viruses · doi:10.3390/v14050916 · Cited by 20
“More recently, during monitoring of the poliomyelitis eradication campaign, the emergence of vaccine-derived recombinant polioviruses (VDRP) have been demonstrated arising from Sabin strains and co-circulating species C enteroviruses [12, 13].”
BackgroundHe, C.-Q., Meng, S., Yan, H., Ding, N., He, H., Yan, J., & Xu, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049992 · Cited by 19
“In fact, some virulent virus strains have been generated by homologous recombination between attenuated vaccine and wild viruses [11,37].”
BackgroundØynebråten, I., Hinkula, J., Fredriksen, A. B., & Bogen, B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104814 · Cited by 19
“In addition, live attenuated pathogens have the very rare potential to revert to a pathogenic form [1].”
BackgroundPoliomyelitis in the United States
Modlin, J. F. (2004) · JAMA · doi:10.1001/jama.292.14.1749 · Cited by 19
Vaccine‐Derived Polioviruses: Is It Time to Stop Using the Word “Rare”?
Dowdle, W. R., & Kew, O. M. (2006) · The Journal of Infectious Diseases · doi:10.1086/506368 · Cited by 19
“The first recognized circulating (c) VDPV (type 1) outbreak caused 21 reported cases of poliomyelitis in 2000-2001 on the island of Hispaniola [9].”
BackgroundSelf-citationMohanty, A., Rohilla, R., Zaman, K., Hada, V., Dhakal, S., Shah, A., Padhi, B. K., Al‐qaim, Z. H., Altawfiq, K. J. A., Tirupathi, R., et al. (2023) · Infezioni in Medicina · doi:10.53854/liim-3102-5 · Cited by 27
John, J. K., Giri, S., Karthikeyan, A. S., Lata, D., Jeyapaul, S., Kasirajan, A., Kumar, N., Dhanapal, P., Jayalakshmi, V., Mohanraj, M., et al. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw595 · Cited by 24
“However, replication of the vaccine poliovirus is associated with a loss of attenuating mutations and, rarely, this reverted OPV may be transmitted and spread in the community as a circulating vaccine–derived poliovirus (cVDPV), causing outbreaks of poliomyelitis in settings of low immunization coverage [1, 2].”
BackgroundNates, S. V., Martínez, L. C., Barril, P. A., Ferreyra, L., Giordano, M. O., Masachessi, G., & Isa, M. B. (2007) · Viral Immunology · doi:10.1089/vim.2006.0071 · Cited by 18
Prevalence of vaccine-derived polioviruses in stools of immunodeficient children in South Africa
Pavlov, D. N., van Zyl, W. B., Heerden, J. V., Kruger, M., Blignaut, L., Grabow, W. O. K., & Ehlers, M. M. (2006) · Journal of Applied Microbiology · doi:10.1111/j.1365-2672.2006.03020.x · Cited by 19
“Polio cases attributed to cVDPV type 1 [which had undergone recombination with nonpolio enteroviruses (NPEVs)] have been found in Haiti, Philippines and the Dominican Republic during 2000 and 2001 (Kew et al. 2002, 2004; Wood and Thorley 2003).”
Background
Metadata
- Authors
- Kew, O., Morris-Glasgow, V., Landaverde, M., Burns, C., Shaw, J., Garib, Z., André, J., Blackman, E., Freeman, C. J., Jorba, J., Sutter, R., Tambini, G., Venczel, L., Pedreira, C., Laender, F., Shimizu, H., Yoneyama, T., Miyamura, T., van der Avoort, H., Oberste, M. S., Kilpatrick, D., Cochi, S., Pallansch, M., & de Quadros, C.
- Affiliations
- Centers for Disease Control and Prevention (US)
- Caribbean Epidemiology Centre (CAREC) Laboratory, Pan American Health Organization (PAHO), 16-18 Jamaica Boulevard, Federation Park, Port-of-Spain, Trinidad and Tobago.
- World Health Organization Regional Office for the Americas (US)
- Ministry of Health, Avenida San Cristóbal esquina Tiradentes, Santo Domingo, Dominican Republic.
- Ministry of Public Health, Port-au-Prince, Haiti.
- PAHO, Calle Pepillo Salcedo, Plaza de la Salud, Santo Domingo, Dominican Republic.
- PAHO, Number 295 Avenue John Brown, Port-au-Prince, Haiti.
- National Institute of Infectious Diseases (JP)
- Polio Laboratory, National Institute of Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, 3720 BA, Bilthoven, Netherlands.
- Division of Vaccines and Immunization, PAHO, 525 Twenty-Third Street, N.W., Washington, DC 20037, USA.
- Corresponding author
- Kew, Olen
- ORCID
- Venue
- Science
- Published
- 2002-04-12
- Volume
- 296
- Issue
- 5566
- Pages
- 356-359
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2101037145
- Cited by
- 600
- References
- 19
- Citations by year
- 2026: 5 · 2025: 13 · 2024: 15 · 2023: 19 · 2022: 20 · 2021: 15 · 2020: 17 · 2019: 17 · 2018: 21 · 2017: 21 · 2016: 26 · 2015: 22 · 2014: 39 · 2013: 26 · 2012: 26
- FWCI
- 25.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- poliomyelitis outbreak, vaccine-derived poliovirus, poliovirus type 1, oral polio vaccine, Hispaniola, Dominican Republic, Haiti, unvaccinated children, low vaccination coverage, paralytic poliomyelitis, wild poliovirus
- MeSH terms
- Adolescent, Animals, Capsid, Child, Child, Preschool, Disease Outbreaks, Dominican Republic, Female, Genes, Viral, Haiti, Humans, Infant, Male, Molecular Sequence Data, Poliomyelitis, Poliovirus Vaccine, Oral, Population Surveillance, Recombination, Genetic, Vaccination, Virulence, Point Mutation, Immunization Programs, Poliovirus, 5' Untranslated Regions, Capsid Proteins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.